Achilles Therapeutics
PublicAchilles Therapeutics is now publicly traded
The data on this page reflects Achilles Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Apr 6, 2021
Last Round
Grant
Jul 21, 2022
Total Funding Raised
$385.4M
Company Overview
Achilles Therapeutics (NAS: ACHL) is a biopharmaceutical company focused on developing innovative cancer immunotherapies that target clonal neoantigens, with ongoing trials for non-small-cell lung cancer and recurrent or metastatic melanoma.
Sector
Healthcare
AI Layer
Infrastructure
Keywords
Achilles Therapeutics Comparables
Compare Achilles Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NEOGAP Therapeutics AB | 68% | |
| Enara Bio | 67% | |
| Infinitopes Precision Immunomics | 66% |
Achilles Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 21, 2022 | ||||
| Grant | May 6, 2021 | ||||
| IPO | Apr 6, 2021 | ||||
| Series C | Nov 17, 2020 | ||||
| Series B | Sep 3, 2019 | ||||
Series A | May 24, 2016 |
Achilles Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B, Series C |
| Forbion Capital Partners | Series B, Series C |
| RA Capital Management | Series C, Series B |
| Boxer Capital | Series C |
| European Commission (Horizon Europe) | Grant |
| Perceptive Advisors | Series B, Series C |
| Syncona | Series B, Series C, Series A |
Achilles Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access